Search Results

On the evening of May 5, Kexing Biopharm announced it had obtained a “Certificate of GMP Compliance of a Manufacturer” granted by the Norwegian Medical Products Agency in accordance with the European Medicines Agency regulations.

TC BioPharm plc announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company’s American Depositary Shares originally issued in December 2023 with an exercise price of £1.5814 per ADS and a term of five years.

TC BioPharm today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024.

TC BioPharm PLC announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell therapies for the treatment of refractory cancers and solid tumors.

On the 24th of May, Kexing Biopharm announced that Shenzhen Kexing Pharmaceutical Co., Ltd., its wholly-owned subsidiary, recently received a Notice of Approval for Drug Clinical Trials from the National Medical Products Administration, approving its clinical trial application for GB08 injection solution developed independently by the company.

PharmAbcine, Inc. announced that its U.S. subsidiary, Wincal Biopharm, Inc. (“WincalBio”), gained agreat attention at the world’s largest ophthalmology conference, Association for Research in Vision and Ophthalmology 2024 (ARVO 2024), when they presented the preclinical data of the eye drop formulation.

TOT BIOPHARM International Company Limited (TOT BIOPHARM, 1875.HK) announced its self-developed Pusintin® (TAB008, bevacizumab injection) has been officially granted approval by the National Medical Products Administration (“NMPA”) for marketing in mainland China (i.e., excluding Hong Kong, Macau and Taiwan regions) for the treatment of patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancer and patients with metastatic colorectal cancer.

Recently, Kexing Biopharm announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first patient and dosing.

TC BioPharm today announced the pricing of a public offering of 1,750,000 of its American Depositary Shares.